On Aug. 17, 2020, Atossa Therapeutics announced that it had enrolled and dosed the first cohort of healthy participants in the Phase 1 clinical study using its proprietary drug candidate AT-301, being administered by nasal spray.

This group of 8 participants received a single dose of either AT-301A (placebo) or AT-301B (active).